Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AC 7700

Known as: AVE8062, Combretastatin A4 Analogue AVE8062, AC7700 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Serine
analogs & derivatives

Narrower (1)

ombrabulin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Combretastatin A-4 analogues with benzoxazolone scaffold: Synthesis, structure and biological activity.
In order to design and synthesize a new class of heterocyclic analogues of natural combretastatin A-4 and its synthetic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
2015
2015
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo…
BACKGROUND Ombrabulin (AVE8062) disrupts the vasculature of established tumours and has shown preclinical synergistic anti-tumour… Expand
Is this relevant?
2014
2014
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
SummaryPurpose Preclinical evidence supports synergy between the vascular disrupting agent ombrabulin and various chemotherapy… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2013
2013
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
PURPOSE The vascular disrupting agent ombrabulin rapidly reduces tumor blood flow and causes necrosis in vivo. A phase I dose… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2007
2007
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
The purpose of this study was to examine the therapeutic efficacy and underlying mechanisms of action of a vascular-disrupting… Expand
Is this relevant?
Review
2004
Review
2004
Vascular targeting agents as cancer therapeutics.
  • Philip E. Thorpe
  • Clinical cancer research : an official journal of…
  • 2004
    • Corpus ID: 1739027
Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2003
2003
Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo.
The in vivo combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin (CDDP) was examined. The… Expand
Is this relevant?
2003
2003
Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of…
A novel combretastatin A-4 derivative, AC7700, which is now in Phase I clinical trials under a new code, AVE8062, has shown… Expand
Is this relevant?
2002
2002
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs
In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1999
1999
A Novel Combretastatin A‐4 Derivative, AC‐7700, Shows Marked Antitumor Activity against Advanced Solid Tumors and Orthotopically Transplanted Tumors
AC-7700, a novel combretastatin A-4 derivative, suppresses the growth of solid tumors by inhibiting tumor perfusion. We evaluated… Expand
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE